GMP IPO Watch
Tata India Pharma & Healthcare Fund
Regular Plan · Payout of Income Distribution cum capital withdrawal option · Tata Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.50% | +3.52% | 165 of 255 |
| 1M | +1.50% | +1.97% | 150 of 255 |
| 3M | -3.72% | -3.45% | 110 of 252 |
| 6M | +2.62% | +2.92% | 93 of 251 |
| YTD | +4.08% | +1.21% | 62 of 255 |
| 1Y | +1.14% | +1.11% | 81 of 232 |
| 2Y | +1.15% | +2.39% | 79 of 187 |
| 3Y | +16.35% | +12.36% | 27 of 142 |
| 5Y | +12.64% | +9.81% | 21 of 102 |
| 7Y | +19.28% | +14.27% | 8 of 84 |
| 10Y | +13.40% | +11.68% | 14 of 68 |
| INCEPTION | +11.09% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +3.14% | +39.40% | -14.66% | 60% | 24% |
| 6M | +6.59% | +64.71% | -13.97% | 62% | 25% |
| 1Y | +14.52% | +73.72% | -18.70% | 66% | 28% |
| 2Y | +15.47% | +44.90% | -8.34% | 84% | 37% |
| 3Y | +16.31% | +28.44% | -5.05% | 88% | 40% |
| 5Y | +16.87% | +29.69% | +7.47% | 100% | 46% |
| 7Y | +16.43% | +21.51% | +6.41% | 100% | 46% |
| 10Y | +12.24% | +13.39% | +10.82% | 100% | 45% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity99.72%
- Debt0.00%
- Cash0.28%
- Other0.00%
Market Cap Split
- Large Cap26.01%
- Mid Cap34.46%
- Small Cap39.25%
- Others0.28%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 37.61 | 41.75 |
| P/B | 5.84 | 6.19 |
| Price / Sales | 5.71 | 5.96 |
| Price / Cash Flow | 28.74 | 30.98 |
| Dividend Yield (%) | 0.87 | 0.61 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 7.99% | -0.44% |
| Abbott | Pharmaceuticals & Biotechnology | 5.94% | +0.50% |
| Healthcare Global Enterprises | Equity | 5.92% | -0.38% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 5.68% | +0.03% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 4.65% | +0.44% |
| Apollo Hospitals | Equity | 4.36% | +0.04% |
| Rainbow Childrens Medicare | Equity | 4.30% | -0.17% |
| Cipla | Pharmaceuticals & Biotechnology | 4.22% | -0.05% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.76% | +3.64% |
| Max Healthcare Institute | Equity | 3.71% | -0.09% |
| Lupin | Pharmaceuticals & Biotechnology | 3.14% | -0.12% |
| Bayer Crop Science | Fertilizers & Agrochemicals | 2.96% | -0.05% |
| Syngene International | Equity | 2.85% | -0.17% |
| Procter & Gamble Health | Pharmaceuticals & Biotechnology | 2.75% | +0.24% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 2.60% | +0.19% |
View all 44 holdings
| PI Industries | Fertilizers & Agrochemicals | 2.59% | +1.64% |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 2.57% | +0.43% |
| Pfizer | Pharmaceuticals & Biotechnology | 2.50% | -0.42% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 2.36% | +0.01% |
| FDC | Pharmaceuticals & Biotechnology | 2.24% | +0.14% |
| Fortis Healthcare | Equity | 1.95% | -1.35% |
| Acutaas Chemicals | Pharmaceuticals & Biotechnology | 1.95% | +0.47% |
| Dr. Lal Path Labs | Equity | 1.76% | +0.10% |
| Aster DM Quality Care | Equity | 1.67% | +0.08% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 1.63% | +0.06% |
| Natco Pharma | Pharmaceuticals & Biotechnology | 1.51% | — |
| Sumitomo Chemical | Fertilizers & Agrochemicals | 1.38% | -0.21% |
| Gillette | Personal Products | 1.23% | +0.14% |
| Navin Fluorine International | Chemicals & Petrochemicals | 1.18% | — |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 0.91% | +0.01% |
| Prasol Chemicals | Chemicals & Petrochemicals | 0.88% | — |
| Symbiotec Pharmalab | Pharmaceuticals & Biotechnology | 0.87% | +0.23% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 0.77% | -2.14% |
| GlaxoSmithKline Pharmaceuticals | Pharmaceuticals & Biotechnology | 0.76% | -1.96% |
| Biocon | Pharmaceuticals & Biotechnology | 0.69% | -0.30% |
| Dr. Agarwal's Health Care | Equity | 0.68% | -0.03% |
| Manipal Health Enterprises | Equity | 0.59% | -0.65% |
| Zim Laboratories | Pharmaceuticals & Biotechnology | 0.58% | +0.09% |
| Sanofi Consumer Healthcare | Pharmaceuticals & Biotechnology | 0.57% | +0.05% |
| Molbio Diagnostics | Equity | 0.54% | -0.33% |
| Gujarat Fluorochemicals | Chemicals & Petrochemicals | 0.53% | — |
| I) REPO | Reverse Repo / TREPS | 0.19% | — |
| CASH / NET CURRENT ASSET | Net Current Assets | 0.09% | — |
| Jubilant Pharmova | Pharmaceuticals & Biotechnology | 0.00% | -0.25% |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 12.47 | 16.32 | Low Volatility |
| 3Y | 13.49 | 16.10 | Low Volatility |
| 5Y | 13.15 | 15.67 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | -0.33 | -0.32 | Below Average |
| 3Y | 0.67 | -0.45 | Above Average |
| 5Y | 0.48 | 0.29 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.21 | 0.19 | Above Average |
| 3Y | 1.74 | 1.14 | Above Average |
| 5Y | 1.43 | 0.96 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.00 | 0.96 | Poor Risk Adjusted Returns |
| 3Y | 1.00 | 0.96 | Poor Risk Adjusted Returns |
| 5Y | 0.96 | 0.95 | Poor Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
More From Tata Asset Management Private Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
| Tata Silver Exchange Traded Fund | +26.44% | — | — | +39.36% |
|
Tata Silver ETF Fund of Fund
Direct Plan · IDCW Reinvestment Option
|
+25.50% | — | — | +37.64% |
|
Tata Nifty Capital Markets Index Fund
Direct Plan · IDCW Payout Option
|
+19.89% | — | — | +21.71% |
|
Tata Nifty MidSmall Healthcare Index Fund
Direct Plan · IDCW Reinvestment Option
|
+17.94% | — | — | +18.48% |
| Tata Gold Exchange Traded Fund | +16.49% | — | — | +32.90% |
|
Tata Gold ETF Fund of Fund
Direct Plan · IDCW Reinvestment Option
|
+16.32% | — | — | +31.66% |
|
Tata Ultra Short Term Fund
Direct Plan · Monthly Reinvestment of Income Distribution cum capital withdrawal option
|
+6.91% | +7.27% | +6.74% | +6.49% |
|
Tata Arbitrage Fund
Direct Plan · Monthly Payout of Income Distribution cum capital withdrawal option
|
+6.71% | +7.42% | +6.95% | +5.88% |
|
Tata Money Market Fund
Direct Plan · Growth Option
|
+6.49% | +7.44% | +6.90% | +6.76% |
|
Tata Liquid Fund
Direct Plan · Growth Option
|
+6.48% | +6.92% | +6.43% | +6.86% |
About This Scheme
Investment Objective
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.
Stated Asset Allocation
Equity & equity related instruments of companies in the Pharma & Healthcare Sectors^ 80% - 100%, Other Equity/Equity related instruments 0% - 20%, Money Market Instruments, other liquid instruments**, gold and/or silver instruments/ETF, InvITs as permitted by SEBI 0% - 20%. The scheme may invest in another scheme under the same asset management company or any other mutual fund without charging any fees, provided that aggregate inter-scheme investment made by all schemes under the same management or in schemes under the management of any other asset management company shall not exceed 5% of the net asset value of the mutual fund. Such investments shall be made in the schemes which are permitted by SEBI from time to time. ** Other liquid instruments include cash, bank deposits with Scheduled Commercial Banks, Government Securities, Treasury bills, Repo on Government securities and any other instruments as specified by the SEBI. Units of Equity Mutual funds will be considered under allocation for Equity and Equity related instruments
Exit Load
0.25% of NAV if redeemed /switched out before 30 days from the date of allotment.
Fund Managers
Rajat Srivastava
Primary
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.